

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's produc⦠read more
Healthcare
Medical Devices
10 years
USD
Exclusive to Premium users
$108.51
Price-0.31%
-$0.34
$6.229b
Mid
-
Premium
Premium
-0.4%
EBITDA Margin-12.1%
Net Profit Margin-8.8%
Free Cash Flow Margin$469.820m
+22.5%
1y CAGR+18.5%
3y CAGR+13.0%
5y CAGR-$87.614m
+40.1%
1y CAGR-1.4%
3y CAGR-26.1%
5y CAGR-$1.54
+44.4%
1y CAGR+3.9%
3y CAGR-20.9%
5y CAGR$769.543m
$999.378m
Assets$229.835m
Liabilities$104.315m
Debt10.4%
-2.7x
Debt to EBITDA-$27.610m
+59.2%
1y CAGR+16.5%
3y CAGR-31.3%
5y CAGR